Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02522325 · ClinicalTrials.gov registry record · Phase 1

Reinforcing Effects of Cocaine During Phendimetrazine Maintenance

A Phase 1 study of Cocaine Use Disorder, sponsored by William Stoops.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT02522325 is a Phase 1 study of Cocaine Use Disorder that has completed, run by William Stoops. The registered enrollment target is 30 participants, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02522325, a Phase 1 study of Cocaine Use Disorder, has completed, sponsored by William Stoops.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Phendimetrazine
  • DRUG Cocaine

Study Locations (1)

Kentucky

  • University of Kentucky Department of Behavioral Science - Lexington

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2015-08
Est. Completion 2018-12
Phase Phase 1

Sponsor

William Stoops

13 total trials

What the Registry Record Tells You About NCT02522325

The ClinicalTrials.gov registry entry for NCT02522325 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (71% lower). The listed sponsor is William Stoops, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02522325 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT02522325 about?

NCT02522325 is a clinical study titled "Reinforcing Effects of Cocaine During Phendimetrazine Maintenance". This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phen...

What is the current status of trial NCT02522325?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-08. Estimated completion is 2018-12.

What conditions does trial NCT02522325 study?

This clinical trial studies the following conditions: Cocaine Use Disorder.

What interventions are being tested in trial NCT02522325?

The interventions under investigation include: Placebo (DRUG), Phendimetrazine (DRUG), Cocaine (DRUG).

Who is sponsoring clinical trial NCT02522325?

This trial is sponsored by William Stoops, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02522325 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.